← Back to Search

Anti-viral

Treatment Arm for Chronic Hepatitis C

Phase 4
Waitlist Available
Research Sponsored by Peter J. Ruane, M.D., Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This study is evaluating the safety and efficacy of a 12 week treatment LDV/SOF FDC in patients with Chronic GT1 or GT4 HCV infection and autoimmune disease

Eligible Conditions
  • Chronic Hepatitis C

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
12 Week treatment with LDV/SOF FDC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LDV/SOF FDC
2014
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

Gilead SciencesIndustry Sponsor
1,130 Previous Clinical Trials
867,087 Total Patients Enrolled
Peter J. Ruane, M.D., Inc.Lead Sponsor
2 Previous Clinical Trials
60 Total Patients Enrolled
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top